A Phase 4 interventional study of Ranibizumab 0.5 mg and Aflibercept 2 mg in Wet Age-Related Macular Degeneration, sponsored by Novartis Pharmaceuticals. Completed at 6 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-07.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.
Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 77th largest by enrollment of the 124 interventional ones that give a count, is one of 7 that started in 2015, is one of 33 in phase 4, and was the 93rd registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Austria, Czechia, Denmark and 10 more countries
Ages 50+
AO GENERIUM · Sites in Russian Federation
Ages 50+
AbbVie · Sites in United States
By country, each count listing its studies:
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 43 · Phase 3 35 · Phase 4 33
First in 2002; this study’s year is marked. 7 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 64 across the 124 interventional studies. Of the 98 that completed or were terminated, 42 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 125 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
81 studies in Macular Degeneration by Novartis: 1 open now, 1 under way, none of them phase 3. Of 79 finished, 41 (52%) have results posted.
Among the 81 studies in Macular Degeneration by Novartis, this one is the 42nd largest by enrollment of the 56 interventional ones that give a count, is one of 4 that started in 2015, is one of 18 in phase 4, and was the 39th registered.
Novartis’s Macular Degeneration studies by the year they started, since 2003.
3 of the studies testing ranibizumab in Macular Degeneration that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04657289Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) | 2027-02-04 |
| NCT05562947Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD) | 2027-06-30 |
| NCT04853251Genentech, Inc.A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) | 2027-07-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 125 studies testing ranibizumab in Macular Degeneration, from their registry updates:
Among Novartis’s 81 in Macular Degeneration:
This tab as a report to print or save as PDF → With an account.
The purpose of the study was to compare the effect of intravitreal injections of ranibizumab and aflibercept on systemic VEGF protein levels in treatment naïve wet neovascular Age-related Macular Degeneration (wAMD) patients in a detailed time course.
A planned study visit schedule was established at the time of baseline visit (day 1) for all patients. Study assessments for patients were performed at screening visit, baseline (day 1), day 2, day 8 (± 1 day to allow for flexibility in scheduling) and as of day 15 through to day 169 at biweekly visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
For either eye:
For study eye:
For fellow eye
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
6 monthly intravitreal injections of 0.5 mg ranibizumab
Drug: Ranibizumab 0.5 mg
3 monthly intravitreal injections of 2 mg aflibercept followed by 3 monthly intravitreal injections of 0.5 mg ranibizumab
Drug: Ranibizumab 0.5 mg · Drug: Aflibercept 2 mg
Administered as an intravitreal injection
Also known as: Lucentis
Administered as an intravitreal injection
Also known as: Eylea
Standardized Area Under the Curve (AUC) for VEGF A Levels by SIMOA (Quanterix's Single Molecule Array) Method for the Comparative Phase
The AUC was calculated using the trapezoidal rule, where all available measurement between Day 1 and Week 12 were used. The AUC was standardized by dividing the calculated value by the number of days from first to last measurement.
Time frame: Baseline up to Week 12 visit (Days 1, 2, 8, 15, 29, 43, 57, 71, 85)
Systemic VEGF-A Protein Levels From Study Week 12 to 24
Systemic VEGF-A protein levels in patients switching from monthly 2 mg aflibercept injections to monthly 0.5 mg ranibizumab compared to patients treated with monthly 0.5 mg ranibizumab from baseline (standardized area under the curve)
Time frame: From study week 12 to 24 (Days 85, 99, 113, 127, 141, 155, 169)
Systemic VEGF-A Levels From Study Week 12 to 24 (Change From Baseline)
Adjustment of systemic VEGF-A levels of patients switching from aflibercept to ranibizumab to levels comparable to baseline or to levels comparable as in patients treated from baseline with ranibizumab
Time frame: From study week 12 to 24
The study included adult patients with active, newly diagnosed, and untreated wAMD. A total of 40 patients were treated at 6 study sites across Germany. Patients were treated in an outpatient setting.
| Milestone | Ranibizumab | Aflibercept and Ranibizumab |
|---|---|---|
| Started | 19 | 22 |
| Full analysis set (fas) | 19 | 21 |
| Safety set (saf) | 19 | 21 |
| Per-protocol set (pps) | 17 | 20 |
| Completed | 18 | 19 |
| Not completed | 1 | 3 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Adverse event | 1 | 2 |
The AUC was calculated using the trapezoidal rule, where all available measurement between Day 1 and Week 12 were used. The AUC was standardized by dividing the calculated value by the number of days from first to last measurement.
| pg/mL | Ranibizumab | Aflibercept and Ranibizumab |
|---|---|---|
| Standardized Area Under the Curve (AUC) for VEGF A Levels by SIMOA (Quanterix's Single Molecule Array) Method for the Comparative Phase | 18.78 ± 8.460 | 33.95 ± 7.659 |
Systemic VEGF-A protein levels in patients switching from monthly 2 mg aflibercept injections to monthly 0.5 mg ranibizumab compared to patients treated with monthly 0.5 mg ranibizumab from baseline (standardized area under the curve)
| pg/mL | Ranibizumab | Aflibercept and Ranibizumab |
|---|---|---|
| Systemic VEGF-A Protein Levels From Study Week 12 to 24 | 17.93 ± 5.316 | 29.07 ± 7.863 |
Adjustment of systemic VEGF-A levels of patients switching from aflibercept to ranibizumab to levels comparable to baseline or to levels comparable as in patients treated from baseline with ranibizumab
| pg/ml | Ranibizumab | Aflibercept and Ranibizumab |
|---|---|---|
| Change from Baseline at Week 12 | -1.37 ± 5.369 | 23.73 ± 13.700 |
| Change from Baseline at Week 14 | -1.00 ± 6.128 | 21.93 ± 15.638 |
| Change from Baseline at Week 16 | -0.01 ± 4.675 | 19.26 ± 16.432 |
| Change from Baseline at Week 18 | 1.99 ± 5.582 | 11.61 ± 10.844 |
| Change from Baseline at Week 20 | 1.62 ± 6.460 | 4.84 ± 11.065 |
| Change from Baseline at Week 22 | 0.66 ± 8.109 | 2.45 ± 8.543 |
| Change from Baseline at Week 24 | -1.18 ± 3.664 | 0.96 ± 9.553 |
Collected over 28 weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab (Up to Month 3) | 0/19 (0%) | 3/19 (15.8%) | 14/19 (73.7%) |
| Ranibizumab (After Month 3) | 0/19 (0%) | 0/19 (0%) | 9/19 (47.4%) |
| Aflibercept and Ranibizumab (Up to Month 3 - Aflibercept) | 0/21 (0%) | 1/21 (4.8%) | 17/21 (81%) |
| Aflibercept and Ranibizumab (After Month 3 - Ranibizumab) | 0/21 (0%) | 3/21 (14.3%) | 17/21 (81%) |
| Event | Ranibizumab (Up to Month 3) | Ranibizumab (After Month 3) | Aflibercept and Ranibizumab (Up to Month 3 - Aflibercept) | Aflibercept and Ranibizumab (After Month 3 - Ranibizumab) |
|---|---|---|---|---|
| Retinal pigment epithelial tearEye disorders | 1/19 | 0/19 | 0/21 | 0/21 |
| PneumoniaInfections and infestations | 1/19 | 0/19 | 0/21 | 0/21 |
| Bone cystMusculoskeletal and connective tissue disorders | 1/19 | 0/19 | 0/21 | 0/21 |
| Benign lung neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/19 | 0/19 | 0/21 | 0/21 |
| Atrial fibrillationCardiac disorders | 0/19 | 0/19 | 1/21 | 1/21 |
| Cardiac failure congestiveCardiac disorders | 0/19 | 0/19 | 0/21 | 1/21 |
| Optic nerve cuppingEye disorders | 0/19 | 0/19 | 0/21 | 1/21 |
| Event | Ranibizumab (Up to Month 3) | Ranibizumab (After Month 3) | Aflibercept and Ranibizumab (Up to Month 3 - Aflibercept) | Aflibercept and Ranibizumab (After Month 3 - Ranibizumab) |
|---|---|---|---|---|
| Conjunctival haemorrhageEye disorders | 3/19 | 1/19 | 5/21 | 2/21 |
| Viral upper respiratory tract infectionInfections and infestations | 3/19 | 2/19 | 2/21 | 4/21 |
| Back painMusculoskeletal and connective tissue disorders | 2/19 | 0/19 | 0/21 | 0/21 |
| Choroidal neovascularisationEye disorders | 0/19 | 0/19 | 1/21 | 2/21 |
| Foreign body sensation in eyesEye disorders | 0/19 | 0/19 | 2/21 | 0/21 |
| Vitreous detachmentEye disorders | 0/19 | 0/19 | 0/21 | 2/21 |
| Sensation of foreign bodyGeneral disorders | 0/19 | 0/19 | 2/21 | 0/21 |
| Intraocular pressure increasedInvestigations | 0/19 | 1/19 | 1/21 | 2/21 |
| Photosensitivity reactionSkin and subcutaneous tissue disorders | 0/19 | 0/19 | 2/21 | 0/21 |
| Aortic valve diseaseCardiac disorders | 1/19 | 0/19 | 0/21 | 0/21 |
Full Analysis Set (FAS)
| Age, Continuous(Years) | Ranibizumab | Aflibercept and Ranibizumab | Total |
|---|---|---|---|
| Mean | 74.3 ± 5.50 | 75.4 ± 8.94 | 74.9 ± 7.43 |
| Sex/Gender, Customized(Participants) | Ranibizumab | Aflibercept and Ranibizumab | Total |
|---|---|---|---|
| Female | 11 | 10 | 21 |
| Male | 8 | 11 | 19 |
| Race/Ethnicity, Customized(Participants) | Ranibizumab | Aflibercept and Ranibizumab | Total |
|---|---|---|---|
| Caucasian | 19 | 21 | 40 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2015 to primary completion in Mar 2017, 23 months.
Results were first posted in May 2019, 2 years 1 month after primary completion.
Of 24 industry-sponsored phase 4 interventional studies under Macular Degeneration, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's 23 months is below that.
Counting every sponsor, half of 45 studies reached it within 26 months; a quarter within 14 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab